Myopia Control Lens Efficacy Percentages: Why 85% Doesn't Mean What You Think

The Headline That Misleads

"MiYOSMART iQ shows ~78–85% reduction in axial elongation vs. single-vision controls."

"Stellest achieves 59% reduction in axial elongation."

These headlines sound impressive. An 85% reduction sounds almost curative. But here's what that number actually means — and more importantly, what it doesn't mean.

What "85% Efficacy" Actually Measures

The clinical study setup:

A company tests their lens in a controlled RCT. They measure axial length (eye elongation) in children wearing the lens vs. a control group wearing regular glasses.

Example calculation (simplified for illustration):

For example, imagine a study where control eyes grow 0.30mm and treatment eyes 0.045mm over 6 months—this would be reported as 85% reduction. Real trials use similar calculations, but the exact numbers vary across studies.

• Real trials in peer-reviewed literature show variable results: some report 59% reduction (Stellest), others 80%+, depending on population, compliance, and measurement methods
• What this means: The lens slowed growth to 15% of the control rate

What this DOESN'T mean:

• ❌ 85% of kids stop all myopia progression (not true)
• ❌ Vision will improve by 85% (not possible)
• ❌ Your child will avoid needing stronger glasses (they still will, just slower)
• ❌ All children will see 85% reduction (individual responses vary widely)

The Gap Between RCT Numbers and Real-World Outcomes

Individual Baseline Progression Rates Vary 5x

This is the critical insight nobody talks about.

Illustrative example only (assumes constant progression rate and stable treatment effect — neither is biologically guaranteed; real outcomes vary). Two 8-year-olds, both starting at -1.50 diopters:

Where Does Your Child Sit on the Progression Spectrum?

Approximate progression rate categories (illustrative ranges based on clinical cohort literature — not population-derived percentiles from a single study; actual distribution depends on age, ethnicity, and study design):

Progression Category	Approximate Annual Rate
Slow progressor	≤ −0.25D/year
Moderate progressor	−0.25 to −0.50D/year
Moderate-fast progressor	−0.50 to −0.75D/year
Fast progressor	≥ −1.00D/year

These categories are pragmatic clinical cut-points, not statistically derived population percentiles. The specific rates vary by population; presenting exact percentile figures (10th, 25th, 50th) implies a precision that the published literature does not support for a general audience.

Critical question you should ask your eye doctor: "Based on my child's measurements so far, where do they sit on the progression spectrum? Are they a slow, average, or fast progressor?"

Why this matters:

If your child is a naturally slow progressor (-0.20D/year), and you add a myopia control lens with high reported efficacy (e.g., ~78–85%):

• Reduction: -0.20D × 0.15 = -0.03D/year
• Improvement: minimal in absolute terms
• May offer smaller absolute benefit — though individual factors like age, axial length percentile, family history, and parental risk tolerance should still inform the decision

If your child is a fast progressor (-1.00D/year), and you add the same lens:

• Reduction: -1.00D × 0.15 = -0.15D/year
• Improvement: absolute benefit is larger and more clinically meaningful
• The diopters saved by age 18 are more substantial — a conversation worth having with your clinician

The Real Questions to Ask Before Choosing Based on Efficacy %

1. What's YOUR Child's Baseline Progression Rate?

• Ask your optometrist: "Looking at my child's refraction history, how many diopters per year are they progressing?"
• You need at least 1–2 years of data for a reasonable estimate when possible
• If you only have 1 year of data, a second year of monitoring may help confirm the rate — but this should not delay treatment in fast progressors. A child progressing ≥1.00D/year or with high axial length for age warrants prompt clinical discussion, not a mandatory waiting period

2. Is My Child a Candidate for High-Efficacy Benefit?

You'll see higher real-world benefit if:

• Baseline progression is fast (-0.75D+/year)
• Child is young (8-12 years old, wider window for intervention)
• Myopia is -1 to -3D at start (more to "save")
• High compliance is realistic (will actually wear the treatment)

You may see lower benefit if:

• Baseline progression is slow (-0.25D/year or less)
• Child is older (e.g., 14–16+), where fewer years remain until natural stabilization in many cases — though individual variation means this is not absolute
• Starting myopia is already high (-6D+)
• Compliance will be inconsistent

3. What's the Absolute Difference Between Options?

Don't compare 78–85% vs 59% — compare the real diopter difference for YOUR child's baseline rate.

Example calculation for a -0.60D/year progressor (illustrative hypothetical only — assumes constant progression rate and stable treatment effect, which are not biologically guaranteed):

Treatment	Efficacy % (source)	New Progression Rate	Diopters by Age 18 (hypothetical)
No treatment	—	-0.60D/year	-9.00D
Stellest (59%)	59% (Bao et al. 2022 RCT, axial length endpoint)	-0.25D/year	-7.75D
MiYOSMART iQ (~78%)	~78% (HOYA interim 6-month data, APAO 2026; conference presentation, manufacturer-sponsored; peer-reviewed publication pending)	-0.13D/year	-6.60D
Atropine 0.01% (~27%)	~27% on refraction (LAMP study Year 1, Yam et al. 2019; children aged 4–12)	-0.44D/year	-8.40D
Atropine + Stellest	~60-70% (estimated; large RCTs still in progress)	-0.18D/year	-7.20D

Interpretation: For this child, the diopter difference between Stellest alone and MiYOSMART iQ alone is 1.40D — meaningful but not transformative. The cost difference may or may not justify it.

The Compliance Factor (Often Bigger Than Efficacy %)

Here's what studies don't always emphasize:

Real example:

• MiYOSMART iQ: 85% efficacy, 12-hour daily requirement
  • Child wears 10 hours/day on average (forgot on weekends, school events)
  • Effective compliance: 85% × (10/12) = 71% real efficacy
• Atropine 0.01%: 30% efficacy, 1 drop per night
  • Child uses drops every night (simple routine)
  • Effective compliance: 30% × 100% = 30% real efficacy
• Combination: Atropine + occasional Stellest when motivated
  • Combined estimated efficacy: ~60% (synergistic effect)
  • Real efficacy: 60% × high compliance = higher outcome than either alone

Bottom Line: How to Interpret Efficacy Numbers

1. The efficacy % means that proportion of the control group's progression rate is prevented — not that myopia stops entirely
2. Your child's baseline progression rate determines the absolute benefit — A fast progressor benefits far more from the same efficacy % than a slow progressor
3. Ask your doctor for YOUR child's projection — "If we do nothing, my child reaches ___D by age 18. With [treatment], they reach ___D. Is the difference worth $X/month?"
4. Compliance beats efficacy % — A simpler treatment used consistently beats a complex treatment used sporadically
5. Combination often wins — Atropine 0.01% (~27% efficacy on refraction, LAMP study) combined with a myopia control spectacle or contact lens (59–78%+ efficacy) may approach ~60–70% combined reduction without over-relying on a single modality. Early data suggest this; large combination RCTs are still in progress.
6. Treat headline numbers with healthy skepticism — Efficacy figures vary by endpoint (refraction vs. axial length), study duration, population, and whether the data are peer-reviewed long-term or interim. Always ask: for which population, over what timeframe, and measured how?